Intersect ENT Inc (NASDAQ:XENT) – Equities research analysts at Leerink Swann issued their Q1 2019 EPS estimates for shares of Intersect ENT in a research report issued to clients and investors on Monday, November 5th. Leerink Swann analyst R. Newitter expects that the medical equipment provider will post earnings of ($0.15) per share for the quarter. Leerink Swann also issued estimates for Intersect ENT’s Q2 2019 earnings at ($0.12) EPS, Q3 2019 earnings at ($0.11) EPS and Q4 2019 earnings at ($0.09) EPS.
Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings results on Monday, November 5th. The medical equipment provider reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. The company had revenue of $24.70 million for the quarter, compared to analyst estimates of $24.09 million. Intersect ENT had a negative return on equity of 15.01% and a negative net margin of 17.22%. The company’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.15) earnings per share.
A number of other analysts have also commented on XENT. BidaskClub lowered Intersect ENT from a “buy” rating to a “hold” rating in a report on Tuesday, July 17th. Canaccord Genuity reaffirmed a “buy” rating on shares of Intersect ENT in a research report on Wednesday, August 1st. ValuEngine downgraded Intersect ENT from a “buy” rating to a “hold” rating in a research report on Thursday, August 2nd. Piper Jaffray Companies lowered their target price on Intersect ENT from $45.00 to $40.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 1st. Finally, Northland Securities reaffirmed a “hold” rating and issued a $28.00 target price on shares of Intersect ENT in a research report on Monday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Intersect ENT currently has an average rating of “Buy” and an average target price of $39.67.
Shares of Intersect ENT stock opened at $32.64 on Wednesday. The stock has a market capitalization of $880.44 million, a PE ratio of -58.29 and a beta of 0.57. Intersect ENT has a one year low of $25.15 and a one year high of $42.95.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Meeder Asset Management Inc. increased its position in Intersect ENT by 565.6% during the second quarter. Meeder Asset Management Inc. now owns 3,987 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 3,388 shares during the last quarter. UBS Group AG grew its position in shares of Intersect ENT by 81.1% in the first quarter. UBS Group AG now owns 4,679 shares of the medical equipment provider’s stock valued at $184,000 after purchasing an additional 2,096 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in shares of Intersect ENT in the second quarter valued at approximately $242,000. Xact Kapitalforvaltning AB acquired a new position in shares of Intersect ENT in the second quarter valued at approximately $247,000. Finally, PNC Financial Services Group Inc. grew its position in shares of Intersect ENT by 2,091.8% in the second quarter. PNC Financial Services Group Inc. now owns 6,707 shares of the medical equipment provider’s stock valued at $252,000 after purchasing an additional 6,401 shares during the last quarter. 90.03% of the stock is currently owned by hedge funds and other institutional investors.
In other Intersect ENT news, insider Lisa D. Earnhardt sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $29.63, for a total transaction of $592,600.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Jeryl L. Hilleman sold 12,833 shares of the business’s stock in a transaction that occurred on Monday, October 8th. The stock was sold at an average price of $27.99, for a total value of $359,195.67. The disclosure for this sale can be found here. In the last ninety days, insiders sold 85,666 shares of company stock worth $2,435,926. 5.90% of the stock is owned by company insiders.
About Intersect ENT
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Featured Article: Yield Curve
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.